PANCREATIC ADENOCARCINOMA

This study tests a new drug called RMC-5127 in people with advanced solid tumors that have a specific KRAS G12V gene change. The drug is given alone or with other medicines to see if it is safe and can shrink tumors. About 574 adults who have already tried other treatments will t…

This study tests if adding a low-dose targeted drug (erlotinib) to standard chemotherapy works better for people with a specific, aggressive type of advanced pancreatic cancer called basal-like. About 104 participants will first have their tumor type identified, then receive eith…

This study tests whether adding a drug called anakinra to standard chemotherapy can help shrink pancreatic tumors before surgery. About 24 adults with pancreatic cancer that can be removed or may become removable will receive the combination. The goal is to see if this approach l…

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or other solid tumors that have a specific protein (CLDN18.2). The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in…

This study tests whether adding two drugs (defactinib and avutometinib) to targeted radiation can help people with advanced pancreatic cancer live longer without their cancer growing. About 36 adults whose cancer is locally advanced or borderline resectable will receive the combi…

This study tests a new way to treat advanced pancreatic cancer by placing tiny devices that release a special type of radiation directly into the tumor. The goal is to see if this is safe and possible for 15 people whose cancer has not responded to chemotherapy or who cannot have…

This study is testing a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. A small device that gives off a special type of radiation is placed directly into the tumor, and patients also receive standard chemotherapy. The main goal is to see…

This early-stage trial tests whether adding the targeted drug sotorasib to standard chemotherapy is safe for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. About 15 adults will receive the combination as their first treatment. The main goal is to c…

This study tests a new drug called GTAEXS617 in 230 adults with advanced solid tumors, including lung, breast, ovarian, pancreatic, and head and neck cancers. The goal is to check the drug's safety, how the body processes it, and whether it can shrink tumors. Participants must ha…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses the patient's own T cells, which are modified in…

This study tests whether a major surgery that removes the pancreatic tumor and visible cancer in the abdomen, followed by heated chemotherapy (HIPEC) directly into the belly, is safe and feasible for people with pancreatic cancer that has spread to the abdomen. Participants must …

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This study tests a new drug called daraxonrasib, which targets a common cancer-driving protein (RAS). It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if the new drug helps people live longer or slows …

This early-phase study tests a new drug, CLSP-1025, designed to direct immune cells to attack tumors that have a specific p53 R175H mutation. The trial enrolls adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have worsened after standard treatments.…

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This program provides the experimental drug daraxonrasib to adults with advanced pancreatic cancer that has spread and worsened after prior treatments. It is for patients who have no good standard options and cannot join a daraxonrasib clinical trial. The goal is to offer a poten…

This early-phase trial is testing whether adding Tumor Treatment Fields (TTF) – a device that sends low-intensity electric fields to the tumor – to a specific chemotherapy combination (protein-bound paclitaxel, cisplatin, and gemcitabine) can help control metastatic pancreatic ca…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests a new treatment for people with advanced pancreatic cancer that has not spread to other organs. It combines a drug that helps the immune system fight cancer (Nivolumab) with a procedure that uses electrical pulses to destroy tumor cells (irreversible electroporat…

This early-phase study tests a powerful mix of five chemotherapy drugs for people with advanced cancers of the pancreas, stomach, bile ducts, or gallbladder that have not been treated yet. The researchers use a genetic test to adjust the dose of one drug (irinotecan) based on how…

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to activate the immune system, followed by an infusion…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new approach for advanced pancreatic cancer that cannot be removed by surgery. Doctors place tiny devices called Alpha DaRT seeds directly into the tumor to deliver a special type of radiation from the inside. The main goals are to see if the procedure is safe …

This study tests a wearable device that creates electric fields (TTFields) combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that can be surgically removed. Participants receive the treatment for three cycles before surgery an…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will be randomly assigned to receive either the new combination or standard ch…

This study tests whether the immunotherapy drug dostarlimab works better than standard chemotherapy as the first treatment for people with advanced cancers that have specific genetic markers (dMMR/MSI). The cancers studied are rare types like pancreatic, stomach, and small bowel …

This study tests an experimental drug called ESK981 in people with advanced pancreatic cancer, certain neuroendocrine tumors, or neuroendocrine prostate cancer. Participants take ESK981 capsules in a 5-days-on, 2-days-off cycle. The main goal is to see if the drug can keep the ca…

This early-phase study tests whether adding two new drugs (elraglusib and retifanlimab) to standard chemotherapy can help people with advanced pancreatic cancer that hasn't been treated before. The main goal is to check safety and find the right dose. Up to 12 adults will take pa…

This early-phase study tests a new drug, ASP2138, that helps the immune system find and attack cancer cells that have a specific marker called CLDN18.2. The study includes adults with advanced stomach, gastroesophageal junction, or pancreatic cancer that cannot be removed by surg…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study is testing a new blood test that looks for tiny particles called exosomes to find pancreatic cancer early. The goal is to see if this test can accurately detect the disease in 2000 adults, including those with and without cancer. If successful, it could lead to a simpl…

This study tests a dye that makes pancreatic cancer cells glow during surgery, helping surgeons see and remove tumors more completely. About 27 adults with pancreatic cancer who are scheduled for surgery will receive the dye before their operation. The goal is to find the best do…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can better detect the spread of pancreatic and bile duct cancers compared to standard CT and MRI scans. About 120 adults with newly diagnosed, potentially curable cancer will receive the new scan. If it proves mo…

This study looks at whether a program of exercise and nutrition (called prehabilitation) can help people aged 65 and older with advanced ovarian or pancreatic cancer get ready for surgery while they receive chemotherapy. The main goal is to see if participants can stick with the …

This study collects blood, tissue, and health information from up to 20,000 people with pancreas diseases like pancreatic cancer or pancreatitis. Researchers will use these samples and data to better understand these conditions and develop better screening methods in the future. …

This study is testing whether wearing a fitness tracker (like a Fitbit) can give doctors a better picture of how active advanced cancer patients are. Researchers want to see if activity levels measured by the device match up with the doctor's usual assessment of a patient's physi…